Although the failure of second line therapy was disappointing,
it meant that Dom became eligible for consideration for CAR T-cell therapy
Although the failure of second line therapy was disappointing,
it meant that Dom became eligible for consideration for CAR T-cell therapy
After discussion of Dom's eligibility with the national panel, Dom was approved for treatment with CAR T-cell therapy. His healthcare team decided to treat him with YESCARTA®.
YESCARTA® is indicated for the treatment of adult patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.2
Learn more about Cancer Drugs Fund (CDF) eligibility criteria for CAR T-cell therapy